AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01107613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opinion leader educational letter
Description: All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader educational letter sent to the primary care provider outlining the needs of this patient.
Study NCT02400944 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
Study NCT02400944 — intervention group
Intervention type: OTHER
Intervention: Saliva and/or urine sample
Description: Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
Study NCT02796508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Non-action video game training
Description: PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
Study NCT02796508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Non-cognitive video game training
Description: 16 training sessions with The Sims over 8-10 weeks in small groups
Study NCT04773990 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biodex Balance System
Description: Subjects will receive several unique training modules using biodex
Study NCT03755986 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ATOMO Diagnostic Test
Description: The ATOMO diagnostic test device is the only intervention used in this study.
Study NCT02982967 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Activity
Description: Recreational Physical Activity (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
Study NCT04773990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: specific physical therapy exercise program
Description: Subjects will receive recommended PT program
Study NCT01370759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleaning capsule
Description: Capsules containing the tested materials aimed to improve colon cleansing
Study NCT00439452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine-Based Collaborative Care
Description: Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
Study NCT00439452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Practice Based Collaborative Care
Description: One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
Study NCT01176565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous nicardipine hydrochloride
Description: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present.
Study NCT02878044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thyroid Decision Aid
Description: The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
Study NCT01737294 — intervention group
Intervention type: DRUG
Intervention: Qutenza exposure
Description: Cutaneous patch
Study NCT02488460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physically active math lessons
Description: The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
Study NCT02017522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 11C-PBR PET
Description: Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.~Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes.
Study NCT02559414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02559414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT01062061 — intervention group
Intervention type: BIOLOGICAL
Intervention: VARIVAX™
Description: Attenuated live varicella vaccine
Study NCT03435562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL electronic cigarette
Description: Effects of JUUL electronic cigarette use.
Study NCT03435562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IQOS electronic cigarette
Description: Effects of IQOS electronic cigarette use.
Study NCT03435562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand cigarette
Description: Effects of own brand cigarette use.
Study NCT01131741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
Study NCT01131741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This group receives 3 mL of saline IV during operation.
Study NCT02455076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide is dispensed via a 1.2 mL prefilled pen with 250 mcg/mL solution for subcutaneous (s.c.) injection and will be administered twice daily starting at 5 mcg per dose, either in the abdomen, thigh or upper arm. Exenatide injections will be given within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart between doses). The exenatide dose will be increased to 10 mcg twice daily after 1 month based on clinical response.
Study NCT02455076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Glargine will be given once daily, at the same time of day. If the BG is between 140-200 mg/dL, the dose will be 0.2 units/kg/day; for BG levels 201-400 mg/dL, the dose will be 0.25 units/kg/day. The patients will be discharged on glargine once daily at 50% of the hospital dose.The total daily dose (TDD) of glargine is based on the patient's fasting BG levels for the last 2 days.~1. FBG >180 mg/dL, no hypoglycemia; glargine increased by 4 IU.~2. FBG >140 mg/dL, no hypoglycemia; glargine increased by 2 IU.~3. FBG 100-140 mg/dL, no hypoglycemia; no change in dosage.~4. FBG 70 - 99 mg/dl, decrease glargine by 4 IU or 10% of TDD.~5. FBG or RBG \< 70 mg/dl, decrease glargine by 8 IU or 20% of TDD.~6. FBG or RBG \< 40 mg/dl, decrease dose of glargine by 30%.
Study NCT02455076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapid-acting insulin analogs
Description: If the BG levels are >140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG> 400 mg/dL, the insulin will be 8,12 or 16 units.
Study NCT01373320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay health advisor interactions
Description: For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.~For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening.
Study NCT00764257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREVELLE Shape
Study NCT00764257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Study NCT03462953 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gingival tissue samples will be harvested
Description: Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls and during periodontal surgery or extraction of hopeless teeth with periodontal disease ..~The dissected gingival samples will be washed in saline solution and fixed in 4% buffered formalin for 48 hours, dehydrated in ascending grades of ethyl alcohol, cleared in xylene and embedded in paraffin and will be subjected to the following:.~1. Sections of 4-5 µm in thickness will be obtained, deparaffinized, rehydrated and subjected to histological staining and histomorphometric analysis.~2. Real time- PCR for TGF-B1 ,Vimenten , E-Cadherin .
Study NCT03327311 — intervention group
Intervention type: DEVICE
Intervention: Bellafill
Description: Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis \& deep dermis).
Study NCT03385278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 20HZ Repetitive Transcranial Magnetic Stimulation
Study NCT00581867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: 40IU insulin aspart applied intranasally
Study NCT00581867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03974737 — intervention group
Intervention type: DEVICE
Intervention: CRI device (non-invasive vitals sign measurement)
Description: Survey administration, Orthostatic vital measurements
Study NCT03631277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photo-activated oral disinfection
Description: Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
Study NCT03631277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
Study NCT03409510 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVB radiation
Description: UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week
Study NCT03002311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epharmix/CareSignal eHealth
Description: The self-scheduling text and phone messaging system was built by Epharmix/CareSignal. Participants in the intervention group began receiving text or voice messages (for landlines) starting 1 hour following ED discharge if during normal business hours, or at 1000 the next business morning. Automated messages were sent up to 3 days in a row or until the participant responded or opted out. The phone system would ultimately connect them directly to their referral provider or clinic to schedule an appointment. Once participants hung up with the referral clinic, the intervention texted or called back to solicit the appointment date. If a date was entered, the system sent reminders at 14 days, 7 days, 3 days, and 1 day before the appointment. After the appointment, the intervention texted or called participants to confirm if they attended.
Study NCT01513681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Tablets 200 mg
Study NCT00939276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)
Description: One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
Study NCT00939276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac ophthalmic suspension vehicle
Description: One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
Study NCT00343200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
Study NCT00343200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viagra (sildenafil citrate)
Description: Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
Study NCT03667560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermacell ADM without basement membrane
Description: Patient will be implanted with Dermacell ADM.
Study NCT03667560 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FlexHD
Description: Patient will be implanted with FlexHD.
Study NCT04484233 — intervention group
Intervention type: DEVICE
Intervention: iAnemia Decision Support System
Description: iAnemia permits to display the appropriate guideline using several inputs about a patient: age, type and delay of the surgery, gender, hemoglobin level, and iron deficiency status.
Study NCT00058604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection of EBV specific CTLs
Description: Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course
Study NCT02397421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
Study NCT02522091 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychology tests
Study NCT01513681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Tablets 200 mg
Study NCT01513681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal®
Description: Lamictal® 200 mg Tablets
Study NCT01513681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal®
Description: Lamictal® 200 mg Tablets
Study NCT06319040 — intervention group
Intervention type: OTHER
Intervention: Tegner Activity Level
Description: Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.
Study NCT06319040 — intervention group
Intervention type: OTHER
Intervention: Lysholm Knee Scoring Scale
Description: Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.
Study NCT03656744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801
Description: HTD1801 tablets, 250mg
Study NCT03656744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets manufactured to mimic HTD1801 tablets
Study NCT00396565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER OROS paliperidone
Description: Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
Study NCT00396565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
Study NCT00396565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
Study NCT03900052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic cane
Description: • A haptic biofeedback cane was designed and manufactured to measure the user applied axial cane load, compare the load to the targeted 20% BW threshold, and then deliver a vibrotactile feedback in the cane handle when the loading was greater than threshold. The cane data acquisition was temporally synchronized to the motion analysis system and recorded axial cane loads at 100 Hz for later analysis. The haptic biofeedback cane consisted of a conventional bariatric walking cane (Patterson Medical Ltd) with a loadcell (Digi-Key100 LBS. Load Cell) placed inside a 3D printed modular cane foot. A microcontroller (Sparkfun™ Pro Micro), SD disk storage (Sparkfun™ OpenLog), eccentric rotating mass vibration motor (model 306-109, Precision Microdrives Limited), USB communications port, and battery completed the system.
Study NCT03900052 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: typical cane
Description: Typical training cane loading training
Study NCT04356794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture needle with electrical stimulation
Description: EA is treated for 4 weeks, 3 times per week.
Study NCT04356794 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham EA is treated for 4 weeks, 3 times per week.
Study NCT01556321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
Study NCT04317079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxytyrosol
Description: Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
Study NCT01556321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]
Description: Subjects will receive green tea (757 mg/capsule \[84.5 mg EGCG + 2.1 mg caffeine \], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
Study NCT01510171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
Study NCT01510171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
Study NCT03668990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IMUs (Xsens, MVN Studio)
Description: It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
Study NCT03500588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Polymerase chain reaction was used to diagnose gene polymorphism.